BR112012019866A2 - composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto - Google Patents

composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto

Info

Publication number
BR112012019866A2
BR112012019866A2 BR112012019866A BR112012019866A BR112012019866A2 BR 112012019866 A2 BR112012019866 A2 BR 112012019866A2 BR 112012019866 A BR112012019866 A BR 112012019866A BR 112012019866 A BR112012019866 A BR 112012019866A BR 112012019866 A2 BR112012019866 A2 BR 112012019866A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
viral infections
treating viral
Prior art date
Application number
BR112012019866A
Other languages
English (en)
Other versions
BR112012019866A8 (pt
Inventor
Wilkinson Barrie
Janet Martin Christine
Alan Gregory Matthew
James Moss Steven
Original Assignee
Biotica Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1002097.2A external-priority patent/GB201002097D0/en
Priority claimed from GBGB1006128.1A external-priority patent/GB201006128D0/en
Priority claimed from GBGB1101085.7A external-priority patent/GB201101085D0/en
Application filed by Biotica Tech Limited filed Critical Biotica Tech Limited
Publication of BR112012019866A2 publication Critical patent/BR112012019866A2/pt
Publication of BR112012019866A8 publication Critical patent/BR112012019866A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto. são fornecidos, inter alia, composto da fómula (i) úteis como inibidores de ciclofilina.
BR112012019866A 2010-02-09 2011-02-09 Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto BR112012019866A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1002097.2A GB201002097D0 (en) 2010-02-09 2010-02-09 Novel compounds
GBGB1006128.1A GB201006128D0 (en) 2010-04-13 2010-04-13 Novel compounds
GBGB1101085.7A GB201101085D0 (en) 2011-01-21 2011-01-21 Novel compounds
PCT/GB2011/050236 WO2011098809A1 (en) 2010-02-09 2011-02-09 Sanglifehrin based compounds

Publications (2)

Publication Number Publication Date
BR112012019866A2 true BR112012019866A2 (pt) 2017-07-11
BR112012019866A8 BR112012019866A8 (pt) 2017-12-26

Family

ID=43836693

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019866A BR112012019866A8 (pt) 2010-02-09 2011-02-09 Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto

Country Status (9)

Country Link
US (1) US9119853B2 (pt)
EP (1) EP2533784B1 (pt)
JP (1) JP5894935B2 (pt)
AU (1) AU2011214135B2 (pt)
BR (1) BR112012019866A8 (pt)
CA (1) CA2788761C (pt)
ES (1) ES2541853T3 (pt)
MX (1) MX2012008873A (pt)
WO (1) WO2011098809A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008123D0 (en) * 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) * 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
US10857150B2 (en) 2016-11-18 2020-12-08 Abliva Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
CA3123869A1 (en) * 2018-12-21 2020-06-25 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
EP0910633B1 (en) 1996-07-05 2009-12-09 Biotica Technology Limited Hybrid polyketide synthase I gene
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
CN101242842A (zh) 2005-06-17 2008-08-13 诺瓦提斯公司 Sanglifehrin在hcv中的用途
WO2008084368A2 (en) 2007-01-04 2008-07-17 Debiopharm Sa Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
EP2342335B1 (en) 2008-09-24 2015-09-16 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
AU2011214135A1 (en) 2012-08-23
BR112012019866A8 (pt) 2017-12-26
JP5894935B2 (ja) 2016-03-30
US20120295841A1 (en) 2012-11-22
AU2011214135B2 (en) 2014-07-31
WO2011098809A1 (en) 2011-08-18
CA2788761C (en) 2018-05-29
JP2013518923A (ja) 2013-05-23
CN102770139A (zh) 2012-11-07
CA2788761A1 (en) 2011-08-18
US9119853B2 (en) 2015-09-01
EP2533784B1 (en) 2015-04-22
EP2533784A1 (en) 2012-12-19
ES2541853T3 (es) 2015-07-27
MX2012008873A (es) 2012-11-22

Similar Documents

Publication Publication Date Title
BR112018009252A2 (pt) tratamento da osteoartrite
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
CR20120296A (es) Nuevos compuestos de espiropiperidina
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
MX2011005934A (es) Compuestos organicos.
EA201301209A1 (ru) Производные пирролотриазинона в качестве ингибиторов p13k
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
ECSP11011184A (es) Compuestos orgánicos
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
MY165087A (en) Neprilysin inhibitors
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201791850A1 (ru) Борсодержащие малые молекулы
IN2014KN00948A (pt)
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
ECSP14013239A (es) Composiciones farmacéuticas
BR112013024965A2 (pt) composto, composição farmacêutica, método de tratamento de infecções virais, e, processo para preparar um composto
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112013016241A2 (pt) composto, e, método para fabricar um composto
BR112015006037A2 (pt) métodos para tratamento de hcv

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIOTICA TECHNOLOGY LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: NEUROVIVE PHARMACEUTICAL AB (SE)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements